Results 31 to 40 of about 12,785,139 (351)

High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor

Journal of Thrombosis and Haemostasis, 2018
Essentials Elevated procoagulant levels are associated with an increased risk of venous thrombosis (VT). The dependency on concurrent increased factor levels and VT was analyzed in a large study.
I. M. Rietveld, W. Lijfering, S. Cessie, M. Bos, F. Rosendaal, P. Reitsma, S. Cannegieter   +6 more
semanticscholar   +1 more source

Calcium Prevents Enhanced Degradation of Factor VIII in the Condition of Motion

Biology, 2023
Background: Hemophilia A and B induce recurrent bleeding episodes, mainly in skeletal muscles and joints that are in intermittent motion. We have previously demonstrated that intermittent motion contributes to increased degradation of factors VIII and IX.
Haim Cohen, Anat Keren-Politansky, Yonatan Crispel, Chen Yanovich, Keren Asayag, Yona Nadir   +5 more
doaj   +1 more source

Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII

Molecular Therapy: Methods & Clinical Development, 2020
It is well known that canine factor VIII (cFVIII) has a higher specific activity than does human FVIII (hFVIII), and it has been previously demonstrated that cFVIII light chain is able to enhance hFVIII activity.
Jenni Firrman, Qizhao Wang, Wenman Wu, Biao Dong, Wenjing Cao, Andrea Rossi Moore, Sean Roberts, Barbara A. Konkle, Carol Miao, LinShu Liu, Dong Li, Weidong Xiao   +11 more
doaj   +1 more source

Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021

Research and Practice in Thrombosis and Haemostasis, 2021
The most serious complication of factor VIII (FVIII) replacement therapy is the occurrence of anti‐FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII products.
Yesim Dargaud, Carmen Escuriola‐Ettingshausen   +1 more
doaj   +1 more source

Safety and efficacy of BAY 94‐9027, a prolonged‐half‐life factor VIII

Journal of Thrombosis and Haemostasis, 2017
Essentials Recombinant factor VIII BAY 94‐9027 conjugates in a site‐specific manner with polyethylene glycol. BAY 94‐9027 was given to patients with severe hemophilia A as prophylaxis and to treat bleeds. BAY 94‐9027 prevented bleeds at dose intervals up
M. Reding, Heng Joo Ng, L. Poulsen, M. E. Eyster, Ingrid Pabinger, H. J. Shin, R. Walsch, Michael Marcel Lederman, Maria Wang, M. Hardtke, Lisa A. Michaels   +10 more
semanticscholar   +1 more source

Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?

Haematologica, 2019
Therapeutic factor VIII is highly immunogenic. Despite intensive research in the last decades, the reasons why 5-30% of patients with hemophilia A (of all severities) develop inhibitory anti-factor VIII antibodies (inhibitors) following replacement ...
Aditi Varthaman, Sébastien Lacroix-Desmazes   +1 more
doaj   +1 more source

Factor VIII/V C-domain swaps reveal discrete C-domain roles in factor VIII function and intracellular trafficking

Haematologica, 2017
Factor VIII C-domains are believed to have specific functions in cofactor activity and in interactions with von Willebrand factor. We have previously shown that factor VIII is co-targeted with von Willebrand factor to the Weibel-Palade bodies in blood ...
Eduard H.T.M. Ebberink, Eveline A.M. Bouwens, Esther Bloem, Mariëtte Boon-Spijker, Maartje van den Biggelaar, Jan Voorberg, Alexander B. Meijer, Koen Mertens   +7 more
doaj   +1 more source

Modelling US health equity impacts of emicizumab for severe haemophilia A: aggregate distributional cost-effectiveness analysis

BMJ Open
Objectives Emicizumab is the first bispecific antibody approved for prophylaxis in people with haemophilia A with or without factor VIII inhibitors. Aggregate distributional cost-effectiveness analysis assesses health equity impacts by evaluating how ...
Randall Curtis, Thomas Majda, Janet S. Lee, Stacey L. Kowal   +3 more
doaj   +1 more source

Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study

Research and Practice in Thrombosis and Haemostasis
Background: The SIPPET randomized clinical trial showed that in previously untreated patients (PUPs) with severe hemophilia A, treatment with plasma-derived factor (F)VIII (pdFVIII) within the first 50 exposure days (EDs) was associated with a lower ...
Syna Miri, Frits R. Rosendaal, Kaan Kavakli, Peyman Eshghi, Soha Mohammadi Moghaddam, Sara Scardo, Behnaz Habibpanah, Mohsen Elalfy, Susan Halimeh, Gabriella Nicolò, Dilek Gökçebay, Namık Özbek, Tiraje Celkan, Ahmad Mohammadi, Mehran Karimi, Amin Shahsavani, Bariş Yılmaz, Canan Albayrak, Burcak Gunes, Zühre Kaya, Yilmaz Ay, Sinan Akbayram, Nazan Sarper, Pier Mannuccio Mannucci, Flora Peyvandi   +24 more
doaj   +1 more source

The factor VIII protein and its function.

Acta Biochimica Polonica, 2016
Factor VIII (FVIII), an essential blood coagulation protein, is a key component of the fluid phase blood coagulation system. Human factor VIII is a single chain of about 300 kDa consisting of domains described as A1-A2-B-A3-C1-C2.
A. Mazurkiewicz-Pisarek, G. Płucienniczak, T. Ciach, A. Plucienniczak   +3 more
semanticscholar   +1 more source